Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-08
2008-04-08
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S276700
Reexamination Certificate
active
11176087
ABSTRACT:
The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.
REFERENCES:
patent: 2004/0242641 (2004-12-01), Buckley et al.
patent: 01/81347 (2001-11-01), None
patent: 2004/106342 (2004-12-01), None
Arneric et al., “Cholingeric channel modulators as a novel therapeutic strategy for Alzheimer's disease,” Exp. Opin. Invest. Drugs 5(1):79-100 (1996).
Arneric et al., “Neuronal nicotinic acetycholine receptors,” Psychopharmacology: The Fourth Generation of Progress 95-110 (1995).
Carty et al., “Cox-2 inhibitors. Potential for reducing NSAID side-effects in treating inflammatory disease,” Emerging Drugs: The Prospect for Improved Medicines, Annual Executive Briefing 1996, Chapter 19, pp. 391-411.
Chaplan et al., “Quantitative assessment of tactile allodynia in the rat paw,” Journal of Neuroscience Methods 53:55-63 (1994).
Cherny, “Opioid Analgesics, Comparative features and prescribing guidelines,” Drugs 51(5):713-737 (1996).
Decker et al., “Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats,” European Journal of Pharmacology 261:217-222 (1994).
Dray et al., “New pharmacological strategies for pain relief,” Annu. Rev. Pharmacol. Toxicol. 36:253-280 (1996).
Dray et al., “Pharmacology of chronic pain,” TiPS 15:190-197 (1994).
Kim et al., “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat,” Pain 50:355-363 (1992).
Lindstrom, “Nicotinic acetylcholine receptors in health and disease,” Molecular Neurobiology 15:193-222 (1997).
Lloyd et al., “The potential of subype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents,” Life Sciences 62(17/18):1601/1606 (1998).
Lukas, “Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line,” Journal of Pharmacology and Experimental Therapeutics 265(1):294-302 (1993).
Pabreza et al, “[3H]cytosine binding to nicotinic cholinergic receptors in brain,” Molecular Pharmacology 39:9-12 (1990).
Prescott et al., Methods in cell biology, vol. XIV, Academic Press, New York, NY, p. 33 et seq. (1976).
Williams et al., “Beyond the tobacco debate: dissecting out the therapeutic potential of nicotine,” Exp. Opin. Invest. Drugs 5(8): 1035-1045 (1996).
Williams et al., “Emerging molecular approaches to pain therapy,” Journal of Medicinal Chemistry 42(9):1481-1500 (1999).
Buckley Michael J.
Hannick Steven M.
Henry Rodger F.
Ji Jianguo
Kotecki Brian J.
Abbott Laboratories
Morris Patricia L.
LandOfFree
(1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3932208